Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering

Computational and Structural Biotechnology Journal

Volumn 15, Issue , 2017, Pages 146-160

  Guha, Tuhin Kumar ^a   Wai, Alvan ^a   Hausner, Georg ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

CRISPR Cas9; Hammerhead ribozyme; Meganuclease; Regulatory switch; TALEN; Zinc finger nuclease

Indexed keywords

DNA; REPAIR; ZINC;

CRISPR/CAS9; EDITING TOOLS; GENE FUNCTION; GENETIC TOOLS; GENOME ENGINEERING; HAMMERHEAD RIBOZYMES; MEGANUCLEASE; REGULATORY SWITCH; TALEN; ZINC FINGER NUCLEASE;

GENES;

DNA; DNA CUTTING ENZYME; ENZYME; HAMMERHEAD RIBOZYME; RIBOZYME; UNCLASSIFIED DRUG;

ALLOSTERISM; ENZYME ENGINEERING; GENE EDITING; GENETIC ENGINEERING; GENETIC REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIBOSWITCH;

EID: 85010676738     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2016.12.006     Document Type: Review

References (250)

1. [1] Kodym, A., Afza, R., Physical and chemical mutagenesis. Methods Mol Biol 236 (2003), 189–204.
2. [2] O'Brien, T.P., Frankel, W.N., Moving forward with chemical mutagenesis in the mouse. J Physiol 554 (2004), 13–21.
3. [3] Chalker, J.M., Davis, B.G., Chemical mutagenesis: selective post-expression interconversion of protein amino acid residues. Curr Opin Chem Biol 14:6 (2010), 781–789.
4. [4] Ivics, Z., Li, M.A., Mátés, L., Boeke, J.D., Nagy, A., et al. Transposon-mediated genome manipulation in vertebrates. Nat Methods 6:6 (2009), 415–422.
5. [5] Muñoz-López, M., García-Pérez, J.L., DNA transposons: nature and applications in genomics. Curr Genomics 11:2 (2010), 115–128.
6. [6] Roland, R., Lena, R., Wang, W., Cadinanos, J., Vassiliou, G., et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 330:6007 (2010), 1104–1107.
7. [7] Frantz, S., Studies reveal potential pitfalls of RNAi. Nat Rev Drug Discov 2 (2003), 763–764.
8. [8] Castanotto, D., Rossi, J.J., The promises and pitfalls of RNA-interference-based therapeutics. Nature 457 (2009), 426–433.
9. [9] von Bubnoff, A., Adenovirus vectors: promise and possible pitfalls. IAVI Rep 16:1 (2012), 4–7.
10. [10] Aiuti, A., Luca, B., Samantha, S., Francesca, F., Maria, P.C., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. Science, 341, 2013, 1233151.
11. [11] Jasin, M., Genetic manipulation of genomes with rare-cutting endonucleases. Trends Genet 12:6 (1996), 224–228.
12. [12] Porteus, M., Seeing the light: integrating genome engineering with double-strand break repair. Nat Methods 8 (2011), 628–630.
13. [13] Kim, H., Kim, J.S., A guide to genome engineering with programmable nucleases. Nat Rev Genet 15 (2014), 321–334.
14. [14] Moore, J.K., Haber, J.E., Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol 16:5 (1996), 2164–2173.
15. [15] Lieber, M.R., The mechanism of double-strand DNA break repair by the nonhomologous DNA end joining pathway. Annu Rev Biochem 79 (2010), 181–211.
16. [16] Choulika, A., Perrin, A., Dujon, B., Nicolas, J.F., Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol Cell Biol 15 (1995), 1968–1973.
17. [17] Li, X., Heyer, W.-D., Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18:1 (2008), 99–113.
18. [18] Moehle, E.A., Rock, J.M., Lee, Y.L., Jouvenot, Y., DeKelver, R.C., et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A 104 (2007), 3055–3060.
19. [19] Lee, H.J., Kim, E., Kim, J.S., Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res 20:1 (2010), 81–89.
20. [20] Söllü, C., Pars, K., Cornu, T.I., Thibodeau-Beganny, S., Maeder, M.L., et al. Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion. Nucleic Acids Res 38:22 (2010), 8269–8276.
21. [21] Gaj, T., Gersbach, C.A., Barbas, C.F. III, ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:7 (2013), 397–405.
22. [22] Lin, F.L., Sperle, K., Sternberg, N., Repair of double-stranded DNA breaks by homologous DNA fragments during transfer of DNA into mouse L cells. Mol Cell Biol 10 (1990), 113–119.
23. [23] Elliott, B., Jasin, M., Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol 21 (2001), 2671–2682.
24. [24] Stark, J.M., Pierce, A.J., Oh, J., Pastink, A., Jasin, M., Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biochem 24:21 (2004), 9305–9316.
25. [25] Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153 (2013), 910–918.
26. [26] Yasue, A., Mitsui, S.N., Watanabe, T., Sakuma, T., Oyadomari, S., et al. Highly efficient targeted mutagenesis in one-cell mouse embryos mediated by the TALEN and CRISPR/Cas systems. Sci Rep, 4, 2014, 5705.
27. [27] Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435 (2005), 646–651.
28. [28] Howe, S.J., Mansour, M.R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118:9 (2008), 3143–3150.
29. [29] Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S.Y., et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475:7355 (2011), 217–221.
30. [30] Zou, J., Mali, P., Huang, X., Dowey, S.N., Cheng, L., Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118:17 (2011), 4599–4608.
31. [31] Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.Q., et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478:7369 (2011), 391–394.
32. [32] Gao, H., Smith, J., Yang, M., Jones, S., Djukanovic, V., et al. Heritable targeted mutagenesis in maize using a designed endonuclease. Plant J 61 (2010), 176–187.
33. [33] Watanabe, K., Breier, U., Hensel, G., Kumlehn, J., Schubert, I., et al. Stable gene replacement in barley by targeted double-strand break induction. J Exp Bot 67:5 (2016), 1433–1445.
34. [34] Deredec, A., Burt, A., Godfray, H.C., The population genetics of using homing endonuclease genes in vector and pest management. Genetics 179 (2008), 2013–2026.
35. [35] Windbichler, D.A., Papathanos, P.A., Catteruccia, F., Ranson, H., Burt, A., et al. Homing endonuclease mediated gene targeting in Anopheles gambiae cells and embryos. Nucleic Acids Res 35 (2007), 5922–5933.
36. [36] Saunders, S., Cooke, B., McColl, K., Shine, R., Peacock, T., Modern approaches for the biological control of vertebrate pests: an Australian perspective. Biol Control 52:3 (2010), 288–295.
37. [37] Chan, Y.-S., Naujoks, D.A., Huen, D.S., Russell, S., Insect population control by homing endonuclease-based gene drive: an evaluation in Drosophila melanogaster. Genetics 188 (2011), 33–44.
38. [38] Chan, Y.-S., Takeuchi, R., Jarjour, J., Huen, D.S., Stoddard, B.L., Russell, S., The design and in vivo evaluation of engineered I-OnuI-based enzymes for HEG gene drive. PLoS One, 8(9), 2013, e74254.
39. [39] Gantz, V.M., Bier, E., The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations. Science 348:6233 (2015), 442–444.
40. [40] Hammond, A., Galizi, R., Kyrou, K., Simoni, A., Siniscalchi, C., et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol 34 (2016), 78–83.
41. [41] Scharenberg AM, Stoddard BL, Monnat RJ, Nolan A (2016) Retargeting: an unrecognized consideration in endonuclease-based gene drive biology. 10.1101/089946.
42. [42] Stoddard, B.L., Homing endonuclease structure and function. Q Rev Biophys 38:1 (2005), 49–95.
43. [43] Silva, G., Poirot, L., Galetto, R., Smith, J., Montoya, G., et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 11:1 (2011), 11–27.
44. [44] Hafez, M., Hausner, G., Homing endonucleases: DNA scissors on a mission. Genome 55:8 (2012), 553–569.
45. [45] Stoddard, B.L., Homing endonucleases from mobile group I introns: discovery to genome engineering. Mob DNA, 5, 2014, 7.
46. [46] Kim, Y.G., Cha, J., Chandrasegaran, S., Hybrid restriction enzymes: zinc finger fusions to FokI cleavage domain. Proc Natl Acad Sci U S A 93 (1996), 1156–1160.
47. 2 zinc finger proteins. Annu Rev Biochem 70 (2001), 313–340.
48. [48] Cathomen, T., Joung, J.K., Zinc-finger nucleases: the next generation emerges. Mol Ther 16:7 (2008), 1200–1207.
49. [49] Carroll, D., Genome engineering with zinc-finger nucleases. GSA 188:4 (2011), 773–782.
50. [50] Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326:5959 (2009), 1509–1512.
51. [51] Christian, M., Cermak, T., Doyle, E.L., Schmidt, C., Zhang, F., et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:2 (2010), 757–761.
52. [52] Boch, J., TALEs of genome targeting. Nat Biotechnol 29:2 (2011), 135–136.
53. [53] Li, T., Huang, S., Jiang, W.Z., Wright, D., Spalding, M.H., et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 39 (2011), 359–372.
54. [54] Bhaya, D., Davison, M., Barrangou, R., CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45 (2011), 273–297.
55. [55] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:6096 (2012), 816–821.
56. [56] Jiang, W., Bikard, D., Cox, D., Zhang, F., Marraffini, L.A., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31:3 (2013), 233–239.
57. [57] Zimmerly, S., Guo, H., Perlman, P.S., Lambowitz, A.M., Group II intron mobility occurs by target DNA-primed reverse transcription. Cell 82 (1995), 545–554.
58. [58] Lambowitz, A.M., Zimmerly, S., Group II introns: mobile ribozymes that invade DNA. Cold Spring Harb Perspect Biol, 3(8), 2011, a003616.
59. [59] Mohr, G., Hong, W., Zhang, J., Cui, G.Z., Yang, Y., A targetron system for gene targeting in thermophiles and its application in Clostridium thermocellum. PLoS One, 8(7), 2013, e69032.
60. [60] Nisa-Martínez, R., Molina-Sánchez, M.D., Toro, N., Host factors influencing the retrohoming pathway of group II intron RmInt1, which has an intron-encoded protein naturally devoid of endonuclease activity. PLoS One, 11(9), 2016, e0162275.
61. [61] Mohr, G., Smith, D., Belfort, M., Lambowitz, A.M., Rules for DNA target-site recognition by a lactococcal group II intron enable retargeting of the intron to specific DNA sequences. Genes Dev 14:5 (2000), 559–573.
62. [62] Karberg, M., Guo, H., Zhong, J., Coon, R., Perutka, J., Lambowitz, A.M., Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. Nat Biotechnol 19 (2001), 1162–1167.
63. [63] Cui, X., Davis, G., Mobile group II intron targeting: applications in prokaryotes and perspectives in eukaryotes. Front Biosci 12 (2007), 4972–4985.
64. [64] Wyman, C., Kanaar, R., DNA double-strand break repair: all's well that ends well. Annu Rev Genet 40 (2006), 363–383.
65. [65] Ciccia, A., Elledge, S.J., The DNA damage response: making it safe to play with knives. Mol Cell 40 (2010), 179–204.
66. [66] Chapman, J.R., Taylor, M.R., Boulton, S.J., Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47 (2012), 497–510.
67. [67] Cristea, S., Freyvert, Y., Santiago, Y., Holmes, M.C., Urnov, F.D., et al. In vivo cleavage of transgene donors promote nuclease-mediated targeted integration. Biotechnol Bioeng 110 (2013), 871–880.
68. [68] Maresca, M., Lin, V.G., Guo, N., Yang, Y., Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res 23 (2013), 539–546.
69. [69] Giles, S.H., Yeo, I., Sadaf, F., Shiva, A., David, J.H., et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20 (1998), 111–112.
70. [70] Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chenn, F.F., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001), 603–606.
71. [71] You, K.T., Li, L.S., Kim, N.-G., Kang, H.J., Koh, K.H., et al. Selective translational repression of truncated proteins from frameshift mutation-derived mRNAs in tumors. PLoS Biol, 5(5), 2007, e109.
72. [72] Ousterout, D.G., Perez-Pinera, P., Thakore, P.I., Kabadi, A.M., Brown, M.T., et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21 (2013), 1718–1726.
73. [73] Li, H.L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., et al. Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep 4:1 (2015), 143–154.
74. [74] Lin, S., Staahl, B.T., Alla, R.K., Doudna, J.A., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife, 3, 2014, e04766.
75. [75] Cai, Y., Laustsen, A., Zhou, Y., Sun, C., Anderson, M.V., et al. Targeted, homology-driven gene insertion in stem cells by ZFN-loaded ‘all-in-one’ lentiviral vectors. Elife, 5, 2016, e12213.
76. [76] Sander, J.D., Joung, J.K., CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32:4 (2014), 347–355.
77. [77] Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:6 (2014), 1262–1278.
78. [78] Enyeart, P.J., Mohr, G., Ellington, A.D., Lambowitz, A.M., Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis. Mob DNA, 5, 2014, 21.
79. [79] Cox, D.B.T., Platt, R.J., Zhang, F., Therapeutic genome editing: prospects and challenges. Nat Med 21:2 (2015), 121–131.
80. [80] Porteus, M.H., Towards a new era in medicine: therapeutic genome editing. Genome Biol, 16, 2015, 286.
81. [81] Maeder, M.L., Gersbach, C.A., Genome-editing technologies for gene and cell therapy. Mol Ther 24:3 (2016), 430–446.
82. [82] Kim, J.S., Genome editing comes of age. Nat Protoc 11 (2016), 1573–1578.
83. [83] Kim, E., Kim, S., Hyoung-Kim, D., Choi, B.-S., Choi, I.K.-Y., et al. Precision genome engineering with programmable DNA-nicking enzymes. Genome Res 22 (2012), 1327–1333.
84. [84] Calos, M.P., Genome editing techniques and their therapeutic applications. Clin Pharmacol Ther, 2016, 10.1002/cpt.542.
85. [85] Singh, A., Chakraborty, D., Maiti, S., CRISPR/Cas9: a historical and chemical biology perspective of targeted genome engineering. Chem Soc Rev, 2016, 10.1039/c6cs00197a.
86. [86] Osborn, M.J., Belanto, J.J., Tolar, J., Voytas, D.F., Gene editing and its application for hematological diseases. Int J Hematol 104 (2016), 18–28.
87. [87] Wang, L., Li, F., Dang, L., Liang, C., Wang, C., et al. In vivo delivery systems for therapeutic genome editing. Int J Mol Sci, 17(5), 2016.
88. [88] Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S.M., et al. PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen bonding rules. Nature 365:6446 (1993), 566–568.
89. [89] Knauert, M.P., Glazer, P.M., Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet 10:20 (2001), 2243–2251.
90. [90] Varshney, G.K., Burgess, S.M., DNA-guided genome editing using structure-guided endonucleases. Genome Biol, 17(1), 2016, 187.
91. [91] Xu, S., Cao, S., Zou, B., Yue, Y., Gu, C., et al. An alternative novel tool for DNA editing without target sequence limitation: the structure-guided nuclease. Genome Biol, 17(1), 2016, 186.
92. [92] Algasaier, S.I., Exell, J.C., Bennet, I.A., Thompson, M.J., Gotham, V.J., et al. DNA and protein requirements for substrate conformational changes necessary for human flap endonuclease-1-catalyzed reaction. J Biol Chem 291:15 (2016), 8258–8268.
93. [93] Grizot, S., Epinat, J.-C., Thomas, S., Duclert, A., Rolland, S., et al. Generation of redesigned homing endonucleases comprising DNA-binding domains derived from two different scaffolds. Nucleic Acids Res 38:6 (2010), 2006–2018.
94. [94] Moure, C.M., Gimble, F.S., Quiocho, F.A., Crystal structure of the intein homing endonuclease PI-SceI bound to its recognition sequence. Nat Struct Biol 9:10 (2002), 764–770.
95. [95] Ashworth, J., Taylor, G.K., Havranek, J.J., Quadri, S.A., Stoddard, B.L., et al. Computational reprogramming of homing endonuclease specificity at multiple adjacent base pairs. Nucleic Acids Res 38:16 (2010), 5601–5608.
96. [96] Belfort, M., Bonocora, R.P., Homing endonucleases: from genetic anomalies to programmable genomic clippers. Methods Mol Biol 1123 (2014), 1–26.
97. [97] Jacoby, K., Lambert, A.R., Scharenberg, A.M., Characterization of homing endonuclease binding and cleavage specificities using yeast surface display SELEX (YSD-SELEX). Nucleic Acids Res, 2016, 10.1093/nar/gkw864.
98. [98] Kanchiswamy, C.N., Maffei, M., Malnoy, M., Velasco, R., Kim, J.-S., Fine-tuning next-generation genome editing tools. Trends Biotechnol, 34, 2016, 7.
99. [99] Takeuchi, R., Lambert, A.R., Nga-Sze Mak, A., Jacoby, K., Dickson, R.J., et al. Tapping natural reservoirs of homing endonucleases for targeted gene modification. Proc Natl Acad Sci U S A 108:32 (2011), 13077–13082.
100. [100] Taylor, G.K., Petrucci, L.H., Lambert, A.R., Baxter, S.K., Jarjour, J., et al. LAHEDES: the LAGLIDADG homing endonuclease database and engineering server. Nucleic Acids Res 40:Web Server issue (2012), W110–W116, 10.1093/nar/gks365.
101. [101] Roberts, R.J., Vincze, T., Posfai, J., Macelis, D., REBASE: restriction enzymes and methyltransferases. Nucleic Acids Res 31:1 (2003), 418–420.
102. [102] Lambert, A.R., Hallinan, J.P., Shen, B.W., Chik, J.K., Bolduc, J.M., et al. Indirect DNA sequence recognition and its impact on nuclease cleavage activity. Structure 24:6 (2016), 862–873.
103. [103] Boissel, S., Jarjour, J., Astrakhan, A., Adey, A., Gouble, A., et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 42:4 (2014), 2591–2601.
104. [104] Li, M.V., Shukla, D., Rhodes, B.H., Lall, A., Shu, J., et al. HomeRun vector assembly system: a flexible and standardized cloning system for assembly of multi-modular DNA constructs. PLoS One, 9(6), 2014, e100948.
105. [105] Liu, J.K., Chen, W.H., Ren, S.X., Zhao, G.P., Wang, J., iBrick: a new standard for iterative assembly of biological parts with homing endonucleases. PLoS One, 9, 2014, e110852.
106. [106] McVey, M., Lee, S.E., MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet 24 (2008), 529–538.
107. [107] Certo, M.T., Gwiazda, K.S., Kuhar, R., Sather, B., Curinga, G., et al. Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat Methods 9 (2012), 973–975.
108. [108] Wolfs, J.M., DaSilva, M., Meister, S.E., Wang, X., Schild-Poulter, C., et al. MegaTevs: single-chain dual nucleases for efficient gene disruption. Nucleic Acids Res 42:13 (2014), 8816–8829.
109. [109] Wolfs, J.M., Hamilton, T.A., Lant, J.L., Laforet, M., Zhang, J., et al. Biasing genome-editing events toward precise length deletions with an RNA-guided TevCas9 dual nuclease. Proc Natl Acad Sci U S A, 2016, 10.1073/pnas.1616343114.
110. [110] Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S., Gregory, P.D., Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:9 (2010), 636–646.
111. [111] Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.-L., et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25 (2007), 778–785.
112. [112] Szczepek, M., Brondani, V., Büchel, J., Serrano, L., Segal, D.J., et al. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol 25 (2007), 786–793.
113. + T cells from HIV-1 infection. Blood 123:1 (2014), 61–69.
114. [114] Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:10 (2014), 901–910.
115. [115] Pattanayak, V., Ramirez, C.L., Joung, J.K., Liu, D.R., Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8 (2011), 765–770.
116. [116] Mino, T., Mori, T., Aoyama, Y., Sera, T., Gene- and protein-delivered zinc finger staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus. PLoS One, 8(2), 2013, e56633.
117. [117] Mino, T., Mori, T., Aoyama, Y., Sera, T., Inhibition of DNA replication of human papillomavirus by using zinc finger-single-chain FokI dimer hybrid. Mol Biotechnol 56:8 (2014), 731–737.
118. [118] Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29 (2011), 143–148.
119. [119] Kim, Y., Kweon, J., Kim, J.S., TALENs and ZFNs are associated with different mutation signatures. Nat Methods, 10, 2013, 185.
120. [120] Doyle, E.L., Booher, N.J., Standage, D.S., Voytas, D.F., Brendel, V.P., et al. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 40:Web Server issue (2012), W117–W122, 10.1093/nar/gks608.
121. [121] Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29 (2011), 731–734.
122. [122] Suzuki, K., Yu, C., Qu, J., Li, M., Yao, X., et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 15:1 (2014), 31–36.
123. [123] Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33 (2015), 175–178.
124. [124] Kleinstiver, B.P., Wang, L., Wolfs, J.M., Kolaczyk, T., McDowell, B., et al. The I-TevI nuclease and linker domains contribute to the specificity of monomeric TALENs. G3 (Bethesda) 4:6 (2014), 1155–1165.
125. [125] Barrangou, R., CRISPR-Cas systems and RNA-guided interference. Wiley Interdiscip Rev RNA 4:3 (2013), 267–278.
126. [126] Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8 (2013), 2281–2308.
127. [127] McCaffrey, J., Sibert, J., Zhang, B., Zhang, Y., Hu, W., et al. CRISPR-CAS9 D10A nickase target-specific fluorescent labeling of double strand DNA for whole genome mapping and structural variation analysis. Nucleic Acids Res, 44(2), 2016, e11, 10.1093/nar/gkv878.
128. [128] Dickinson, D.J., Goldstein, B., CRISPR-based methods for Caenorhabditis elegans genome engineering. Genetics 202:3 (2016), 885–901.
129. [129] Karvelis, T., Gasiunas, G., Miksys, A., Barrangou, R., Horvath, P., et al. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol 10:5 (2013), 841–851.
130. [130] Hou, Z., Zhang, Y., Propson, N.E., Howden, S.E., Chu, L.F., et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A 110:39 (2013), 15644–15649.
131. [131] Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Topkar, V.V., Nguyen, N.T., et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:7561 (2015), 481–485.
132. [132] Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:5 (2013), 1173–1183.
133. [133] Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A 109(39): E2579-E2586.
134. [134] Maeder, M.L., Linder, S.J., Cascio, V.M., Fu, Y., Ho, Q.H., et al. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:10 (2013), 977–979.
135. [135] Mali, P., Aach, J., Stranges, P.B., Esvelt, K.M., Moosburner, M., Kosuri, S., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31 (2013), 833–838.
136. [136] Xu, T., Li, Y., Van Nostrand, J.D., He, Z., Zhou, J., Cas9-based tools for targeted genome editing and transcriptional control. Appl Environ Microbiol 80:5 (2014), 1544–1552.
137. [137] Young, S.A., Aitken, R.J., Ikawa, M., Advantages of using the CRISPR/Cas9 system of genome editing to investigate male reproductive mechanisms using mouse models. Asian J Androl 17:4 (2015), 623–627.
138. [138] Lackner, D.H., Carré, A., Guzzardo, P.M., Banning, C., Mangena, R., et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat Commun, 6, 2015, 10237.
139. [139] Zalatan, J.G., Lee, M.E., Almeida, R., Gilbert, L.A., Whitehead, E.H., et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160 (2015), 339–350.
140. [140] Didovyk, A., Borek, B., Tsimring, L., Hasty, J., Transcriptional regulation with CRISPR-Cas9: principles, advances, and applications. Curr Opin Biotechnol 40 (2016), 177–184.
141. [141] Mandegar, M.A., Huebsch, N., Frolov, E.B., Shin, E., Truong, A., et al. CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. Cell Stem Cell 18 (2016), 541–553.
142. [142] Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155:7 (2013), 1479–1491.
143. [143] Tsai, S.Q., Wyvekens, N., Khayter, C., Foden, J.A., Thapar, V., et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32 (2014), 569–576.
144. [144] Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
145. [145] Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:2 (2014), 440–455.
146. [146] Ousterout, D.G., Kabadi, A.M., Thakore, P.I., Majoros, W.H., Reddy, T.E., et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun, 6, 2015, 6244.
147. [147] Kaur, K., Tandon, H., Gupta, A.K., Kumar, M., CrisprGE: a central hub of CRISPR/Cas-based genome editing. Database (Oxford), 2015, bav055, 10.1093/database/bav055.
148. [148] Calos, M.P., The CRISPR way to think about Duchenne's. N Engl J Med 374 (2016), 1684–1686.
149. [149] Peng, R., Lin, G., Li, J., Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS J 283:7 (2016), 1218–1231.
150. [150] Ledford, H., CRISPR, the disruptor. Nature 522 (2015), 20–24.
151. [151] Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154 (2013), 1380–1389.
152. [152] Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 11 (2014), 399–402.
153. [153] Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M., Joung, J.K., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32:3 (2014), 279–284.
154. [154] Esvelt, K.M., Mali, P., Braff, J.L., Moosburner, M., Yaung, S.J., et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10 (2013), 1116–1121.
155. [155] Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163:3 (2015), 759–771.
156. [156] Li, S.Y., Zhao, G.P., Wang, J., C-Brick: a new standard for assembly of biological parts using Cpf1. ACS Synth Biol, 2016, 10.1021/acssynbio.6b00114.
157. [157] Fonfara, I., Richter, H., Bratovič, M., Rhun, A.L., Charpentier, E., The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature 532 (2016), 517–521.
158. [158] Kleinstiver, B.P., Tsai, S.Q., Prew, M.S., Nguyen, N.T., Welch, M.M., et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol 34:8 (2016), 869–874.
159. [159] Kim, D., Kim, J., Hur, J.K., Been, K.W., Yoon, S.H., Kim, J.S., Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol 34:8 (2016), 863–868.
160. [160] Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191.
161. [161] Slaymaker, I.M., Gao, L., Zetsche, B., Scott, D.A., Yan, W.X., et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351:6268 (2015), 84–88.
162. [162] Komor, A.C., Yongjoo, B.K., Packer, M.S., Zuris, J.A., Liu, D.R., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533 (2016), 420–424.
163. [163] Harris, R.S., Petersen-Mahrt, S.K., Neuberger, M.S., RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 10 (2002), 1247–1253.
164. [164] Nelles, D.A., Fang, M.Y., O'Connell, M.R., Xu, J.L., Markmiller, S.J., et al. Programmable RNA tracking in live cells with CRISPR/Cas9. Cell 165:2 (2016), 488–496.
165. [165] Knauert, M.P., Glazer, P.M., Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet 10:20 (2001), 2243–2251.
166. [166] Abibi, A., Protozanova, E., Demidov, V.V., Frank-Kamenetskii, M.D., Specific versus nonspecific binding of cationic PNAs to duplex DNA. Biophys J 86:5 (2004), 3070–3078.
167. [167] Anstaett, P., Gasser, G., Peptide nucleic acid - an opportunity for bio nanotechnology. Chimia 68:4 (2014), 264–268.
168. [168] Pingoud, A., Jeltsch, A., Structure and function of type II restriction endonucleases. Nucleic Acids Res 29 (2001), 3705–3727.
169. [169] Pingoud, A., Fuxreiter, M., Pingoud, V., Wende, W., Type II restriction endonucleases: structure and mechanism. Cell Mol Life Sci 62 (2005), 685–707.
170. [170] Silanskas, A., Zaremba, M., Sasnauskas, G., Siksnys, V., Catalytic activity control of restriction endonuclease-triplex forming oligonucleotide conjugates. Bioconjug Chem 23:2 (2012), 203–211.
171. [171] Devi, G., Zhou, Y., Zhong, Z., Toh, D.F., Chen, G., RNA triplexes: from structural principles to biological and biotech applications. Wiley Interdiscip Rev RNA 6:1 (2012), 111–128.
172. [172] Gao, F., Shen, X.Z., Jiang, F., Wu, Y., Han, C., DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol 34:7 (2016), 768–773.
173. [173] Cyranoski, D., Replications, ridicule and a recluse: the controversy over NgAgo gene-editing intensifies. Nature 536:7615 (2016), 136–137.
174. [174] Thyagarajan, B., Olivares, E.C., Hollis, R.P., Ginsburg, D.S., Calos, M.P., Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 21 (2001), 3926–3934.
175. [175] Bertoni, C., Jarrahian, S., Wheeler, T.M., Li, Y., Olivares, E.C., et al. Enhancement of plasmid-mediated gene therapy for Duchenne muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci U S A 103 (2006), 419–424.
176. [176] Sauer, B., Henderson, N., Cre-stimulated recombination at loxP containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 17 (1989), 147–161.
177. [177] Groth, A.C., Olivares, E.C., Thyagarajan, B., Calos, M.P., A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A 97 (2000), 5995–6000.
178. [178] Grindley, N.D.F., Whiteson, K.L., Rice, P.A., Mechanisms of site specific recombination. Annu Rev Biochem 75 (2006), 567–605.
179. [179] Chalberg, T.W., Portlock, J.L., Olivares, E.C., Thyagarajan, B., Kirby, P.J., et al. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 357 (2006), 28–48.
180. [180] Chavez, C.L., Calos, M.P., Therapeutic applications of the phiC31 integrase system. Curr Gene Ther 11 (2011), 375–381.
181. [181] Zhao, C., Farruggio, A.P., Bjornson, C.R.R., Chavez, C.L., Geisinger, J.M., et al. Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One, 9(4), 2014, e96279.
182. [182] Posey, K.L., Gimble, F.S., Insertion of a reversible redox switch into a rare-cutting DNA endonuclease. Biochemistry 41:7 (2002), 2184–2190.
183. [183] Guha, T.K., Hausner, G., A homing endonuclease with a switch: characterization of a twintron encoded homing endonuclease. Fungal Genet Biol 65 (2014), 57–68.
184. [184] Guha, T.K., Hausner, G., Using group II introns for attenuating the in vitro and in vivo expression of a homing endonuclease. PLoS One, 11(2), 2016, e0150097.
185. [185] Guha, T.K., Hausner, G., Insertion of ribozyme based switches into homing endonuclease genes. Reeves, A., (eds.) Methods in molecular biology—in vitro mutagenesis: methods and protocols, Vol. 1498, 2016, Springer Verlag, 135–152.
186. [186] Dai, L., Toor, N., Olson, R., Keeping, A., Zimmerly, S., Database for mobile group II introns. Nucleic Acids Res 31:1 (2003), 424–426.
187. [187] Candales, M.A., Duong, A., Hood, K.S., Li, T., Neufeld, R.A., et al. Database for bacterial group II introns. Nucleic Acids Res 40:Database issue (2012), D187–D190.
188. [188] Abebe, M., Candales, M.A., Duong, A., Hood, K.S., Li, T., A pipeline of programs for collecting and analyzing group II intron retroelement sequences from GenBank. Mob DNA, 4, 2013, 28.
189. [189] Bonen, L., Cis- and trans-splicing of group II introns in plant mitochondria. Mitochondrion 8 (2008), 26–34.
190. [190] Merendino, L., Perron, K., Rahire, M., Howald, I., Rochaix, J.D., et al. A novel multifunctional factor involved in trans-splicing of chloroplast introns in Chlamydomonas. Nucleic Acids Res 34 (2006), 262–274.
191. [191] Quiroga, C., Kronstad, L., Ritlop, C., Filion, A., Cousineau, B., Contribution of base pairing interactions between group II intron fragments during trans-splicing in vivo. RNA 17 (2011), 2212–2221.
192. [192] Mastroianni, M., Watanabe, K., White, T.B., Zhuang, F., Vernon, J., et al. Group II intron-based gene targeting reactions in eukaryotes. PLoS One, 3(9), 2008, e3121.
193. [193] Truong, D.M., Sidote, D.J., Russell, R., Lambowitz, A.M., Enhanced group II intron retrohoming in magnesium-deficient E. coli via selection of mutations in the ribozyme core. Proc Natl Acad Sci U S A 110 (2013), 3800–3809.
194. [194] Truong, D.M., Hewitt, F.C., Hanson, J.H., Cui, X., Lambowitz, A.M., Retrohoming of a mobile group II intron in human cells suggests how eukaryotes limit group II intron proliferation. PLoS Genet, 11, 2015, e1005422.
195. [195] Cho, S.W., Lee, J., Carroll, D., Kim, J.-S., Lee, J., Heritable gene knockout in Caenorhabditis elegans by direct injection of Cas9-sgRNA ribonucleoproteins. Genetics 195:3 (2013), 1177–1180.
196. [196] Kim, S., Kim, D., Cho, S.W., Kim, J., Kim, J.-S., Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24:6 (2014), 1012–1019.
197. [197] Yoshioka, S., Fujii, W., Ogawa, T., Sugiura, K., Naito, K., Development of a mono-promoter-driven CRISPR/Cas9 system in mammalian cells. Sci Rep, 5, 2015, 18341.
198. [198] Cao, J., Wu, L., Zhang, S.M., Lu, M., Cheung, W.K.C., et al. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. Nucleic Acids Res, 2016, 10.1093/nar/gkw660.
199. [199] Wright, A.V., Sternberg, S.H., Taylor, D.W., Staahl, B.T., Bardales, J.A., et al. Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci U S A 112:10 (2015), 2984–2989.
200. [200] Dow, L.E., Fisher, J., O'Rourke, K.P., Muley, A., Kastenhuber, E.R., et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33 (2015), 390–394.
201. [201] Zetsche, B., Volz, S.E., Zhang, F., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol 33 (2015), 139–142.
202. [202] Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
203. [203] Schierling, B., Noël, A.J., Wende, W., Hien le, T., Volkov, E., et al. Controlling the enzymatic activity of a restriction enzyme by light. Proc Natl Acad Sci U S A 107:4 (2010), 1361–1366.
204. [204] Zaremba, M., Siksnys, V., Molecular scissors under light control. Proc Natl Acad Sci U S A 107:4 (2010), 1259–1260.
205. [205] Brieke, C., Rohrbach, F., Gottschalk, A., Mayer, G., Heckel, A., Light-controlled tools. Angew Chem Int Ed Engl 51 (2012), 8446–8476.
206. [206] Nihongaki, Y., Kawano, F., Nakajima, T., Sato, M., Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol 33:7 (2015), 755–760.
207. [207] Kawano, I., Suzuki, H., Furuya, A., Sato, M., Engineered pairs of distinct photoswitches for optogenetic control of cellular proteins. Nat Commun, 6, 2015, 6256.
208. [208] Zuris, J.A., Thompson, D.B., Shu, Y., Guilinger, J.P., Bessen, J.L., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:1 (2015), 73–80.
209. [209] Goodsell, D.S., The molecular perspective: ultraviolet light and pyrimidine dimers. Oncologist 6:3 (2001), 298–299.
210. [210] Sinha, R.P., Häder, D.P., UV-induced DNA damage and repair: a review. Photochem Photobiol Sci 1:4 (2002), 225–236.
211. [211] Davis, K.M., Pattanayak, V., Thompson, D.B., Zuris, J.A., Liu, D.R., Small molecule triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol 11 (2015), 316–318.
212. [212] Liu, K.I., Ramli, M.N.B., Woo, C.W.A., Wang, Y., Zhao, T., et al. A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. Nat Chem Biol 12 (2016), 980–987.
213. [213] Guilinger, J.P., Thompson, D.B., Liu, D.R., Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32:6 (2014), 577–582.
214. [214] Banaszynski, L.A., Chen, L., Maynard-Smith, L.A., Ooi, A.G.L., Wandless, T.J., A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126:5 (2006), 995–1004.
215. [215] Armstrong, C.M., Goldberg, D.E., An FKBP destabilization domain modulates protein levels in Plasmodium falciparum. Nat Methods 4 (2007), 1007–1009.
216. [216] Pruett-Miller, S.M., Reading, D.W., Porter, S.N., Porteus, M.H., Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet, 5(2), 2009, e1000376.
217. [217] Senturk S, Shirole NH, Nowak DD, Corbo V, Vaughan A, et al. (2015) A rapid and tunable method to temporally control Cas9 expression enables the identification of essential genes and the interrogation of functional gene interactions in vitro and in vivo. 10.1101/023366.
218. [218] Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., et al. Naturally occurring off-switches for CRISPR-Cas9. Cell, 2016, 10.1016/j.cell.2016.11.017.
219. [219] Grabow, W., Jaeger, L., RNA modularity for synthetic biology. F1000Prime Rep, 5, 2013, 46.
220. [220] Ellington, A.D., Szostak, J.W., In vitro selection of RNA molecules that bind specific ligands. Nature 346:6287 (1990), 818–822.
221. [221] Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:4968 (1990), 505–510.
222. [222] Li, Y., A quarter century of in vitro selection. J Mol Evol 81:5–6 (2015), 137–139.
223. [223] Link, K.H., Breaker, R.R., Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches. Gene Ther 16:10 (2009), 1189–1201.
224. [224] Li, Z., Rana, T.M., Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:8 (2014), 622–638.
225. [225] Scott, W.G., Horan, L.H., Martick, M., The hammerhead ribozyme: structure, catalysis, and gene regulation. Prog Mol Biol Transl Sci 120 (2013), 1–23.
226. [226] Prody, G.A., Bakos, J.T., Buzayan, J.M., Schneider, I.R., Bruening, G., Autolytic processing of dimeric plant virus satellite RNA. Science 231:4745 (1986), 1577–1580.
227. [227] Müller, S., Appel, B., Balke, D., Hieronymus, R., Nübel, C., Thirty-five years of research into ribozymes and nucleic acid catalysis: where do we stand today?. F1000Res, 5, 2016.
228. [228] Roth, A., Weinberg, Z., Chen, A.G., Kim, P.B., Ames, T.D., et al. A widespread self-cleaving ribozyme class is revealed by bioinformatics. Nat Chem Biol 10:1 (2014), 56–60.
229. [229] Weinberg, Z., Kim, P.B., Chen, T.H., Li, S., Harris, K.A., et al. New classes of self-cleaving ribozymes revealed by comparative genomics analysis. Nat Chem Biol 11:8 (2015), 606–610.
230. [230] Ruffner, D.E., Stormo, G.D., Uhlenbeck, O.C., Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29:47 (1990), 10695–10702.
231. [231] Hammann, C., Luptak, A., Perreault, J., de la Peña, M., The ubiquitous hammerhead ribozyme. RNA 18:5 (2012), 871–885.
232. [232] O'Rourke, S.M., Estell, W., Scott, W.G., Minimal hammerhead ribozymes with uncompromised catalytic activity. J Mol Biol 427:14 (2015), 2340–2347.
233. [233] Iyo, M., Kawasaki, H., Taira, K., Maxizyme technology. Methods Mol Biol 252 (2004), 257–265.
234. [234] Khvorova, A., Lescoute, A., Westhof, E., Jayasena, S.D., Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat Struct Biol 10:9 (2003), 708–712.
235. [235] Simorre, J.P., Legault, P., Baidya, N., Uhlenbeck, O.C., Maloney, L., et al. Structural variation induced by different nucleotides at the cleavage site of the hammerhead ribozyme. Biochemistry 37:12 (1998), 4034–4044.
236. [236] Beilstein, K., Wittmann, A., Grez, M., Suess, B., Conditional control of mammalian gene expression by tetracycline-dependent hammerhead ribozymes. ACS Synth Biol 4:5 (2015), 526–534.
237. [237] Pelletier, J., Sonenberg, N., Insertion mutagenesis to increase secondary structure within the 5′ noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 40:3 (1985), 515–526.
238. [238] Win, M.N., Smolke, C.D., A modular and extensible RNA-based gene-regulatory platform for engineering cellular function. Proc Natl Acad Sci U S A 104:36 (2007), 14283–14288.
239. [239] Wyszko, E., Szymański, M., Zeichhardt, H., Müller, F., Barciszewski, J., Erdmann, V.A., Spiegelzymes: sequence specific hydrolysis of L-RNA with mirror image hammerhead ribozymes and DNAzymes. PLoS One, 8(1), 2013, e54741.
240. [240] Wyszko, E., Mueller, F., Gabryelska, M., Bondzio, A., Popenda, M., et al. Spiegelzymes® mirror-image hammerhead ribozymes and mirror-image DNAzymes, an alternative to siRNAs and microRNAs to cleave mRNAs in vivo?. PLoS One, 9(1), 2014, e86673.
241. [241] Griffin, L.C., Tidmarsh, G.F., Bock, L.C., Toole, J.J., Leung, L.L., In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:12 (1993), 3271–3276.
242. [242] Saragliadis, A., Krajewski, S.S., Rehm, C., Narberhaus, F., Hartig, J.S., Thermozymes: synthetic RNA thermometers based on ribozyme activity. RNA Biol 10:6 (2013), 1010–1016.
243. [243] Machtel, P., Bąkowska-Żywicka, K., Żywicki, M., Emerging applications of riboswitches — from antibacterial targets to molecular tools. J Appl Genet, 2016, 10.1007/s13353-016-0341-x.
244. [244] Batey, R.T., Riboswitches: still a lot of undiscovered country. RNA 21:4 (2015), 560–563.
245. [245] Lee, E.R., Baker, J.L., Weinberg, Z., Sudarsan, N., Breaker, R.R., An allosteric self-splicing ribozyme triggered by a bacterial second messenger. Science 329:5993 (2010), 845–848.
246. [246] Klein, D.J., Ferré-D'Amaré, A.R., Structural basis of glmS ribozyme activation by glucosamine-6-phosphate. Science 313:5794 (2006), 1752–1756.
247. [247] Porta, H., Lizardi, P.M., An allosteric hammerhead ribozyme. Biotechnology (N Y) 13:2 (1995), 161–164.
248. [248] Thompson, K.M., Syrett, H.A., Knudsen, S.M., Ellington, A.D., Group I aptazymes as genetic regulatory switches. BMC Biotechnol, 2, 2002, 21.
249. [249] Ogawa, A., Maeda, M., An artificial aptazyme-based riboswitch and its cascading system in E. coli. Chembiochem 9:2 (2008), 206–209.
250. [250] Wieland, M., Hartig, J.S., Improved aptazyme design and in vivo screening enable riboswitching in bacteria. Angew Chem Int Ed Engl 47:14 (2008), 2604–2607.